Home > Healthcare > Biotechnology > Biotechnology R&D > Bioreactors Market

Bioreactors Market Trends

Report ID: GMI141
Published Date: Aug 2024
Report Format: PDF

Download Free Sample

Bioreactors Market Trends

The shift towards single-use bioreactors, which offer advantages such as reduced risk of cross-contamination, lower capital investment, and greater flexibility, making them particularly attractive for small-scale and multiproduct manufacturing facilities is expected to significantly boost market growth.
Additionally, advancements in bioreactor technology, such as the integration of automation and real-time monitoring systems, are enhancing process efficiency and product quality.
Furthermore, an escalating demand for biopharmaceuticals, such as monoclonal antibodies, which was valued at USD 186.6 billion in 2022, vaccines, and cell and gene therapies, is a prominent trend. Given the intricate cell culture processes these therapies entail, the market for advanced bioreactors has witnessed a notable upswing.

Authors: Mariam Faizullabhoy , Gauri Wani

Frequently Asked Questions (FAQ) :

The market was valued at USD 10.4 billion in 2023 and is expected to record an 11.8% CAGR between 2024 and 2032, spurred by rising demand for biopharmaceuticals and advancements in bioreactor technology.

The mammalian cells segment was valued at USD 8.3 billion in 2023, as bioreactors offer a controlled environment to manage environmental changes, ensuring optimal cell growth & productivity.

North America bioreactors market is expected to hit USD 10.9 billion by 2032, due to the presence of major biopharmaceutical companies and research institutions, that are pioneering new therapies.

Altrad Group, Bbi-biotech, Getinge AB, Cellexus, CerCell A/S, BaiLun Biotechnology Co., Ltd., Danaher Corporation, Eppendorf Group, Donaldson Company, Inc., GEA Group Aktiengesellschaft, Esco Micro Pte. Ltd., Merck KGaA, Sartorius AG, PBS Biotech, Inc., Thermo Fisher Scientific Inc.